• Clinical Evidence

EndoTool IV Leads to Over 55% Fewer Blood Glucose Checks With an 84% Decrease in Hypoglycemic Events at UPMC

Image
Setting: UPMC Harrisburg hospital

Objective

Investigating the impact of implementing EndoTool IV (ETIV), a computerized insulin dosing algorithm, in the treatment of diabetic ketoacidosis (DKA) across a 7-hospital system in Central Pennsylvania.

Setting

UPMC Harrisburg hospital, part of the larger UPMC seven hospital system in Central Pennsylvania. Two distinct time periods were utilized for comparison of outcomes: September to December 2021, representing the pre-implementation phase of the EndoTool IV (ETIV) computerized insulin dosing algorithm, and September to December 2022, reflecting the post-implementation phase.

Results

This study highlights the potential benefits of using EndoTool IV to manage complex conditions like DKA, with a focus on both clinical and economic outcomes.

  • Incidence of hypoglycemic events reduced from 2.26% to 0.35%, a significant decrease of approximately 84.5%.
  • The number of blood glucose checks decreased by 55%.
  • Average hospital length of stay decreased from 5.1 to 4.5 days.
  • Time required for insulin infusion decreased from 37.2 hours to 35.41 hours, a reduction of 1.79 hours approximately.

Conclusions

  • Clinical Improvements: EndoTool IV led to fewer hypoglycemic events, fewer glucose checks, and shorter infusion times.
  • Financial Impact: While there was no significant reduction in ICU charges, EndoTool IV shows promise in improving clinical outcomes for DKA patients.
  • Future Directions: Further subgroup analysis is being conducted to explore the results in more detail.

Objective

Investigating the impact of implementing EndoTool IV (ETIV), a computerized insulin dosing algorithm, in the treatment of diabetic ketoacidosis (DKA) across a 7-hospital system in Central Pennsylvania.

Setting

UPMC Harrisburg hospital, part of the larger UPMC seven hospital system in Central Pennsylvania. Two distinct time periods were utilized for comparison of outcomes: September to December 2021, representing the pre-implementation phase of the EndoTool IV (ETIV) computerized insulin dosing algorithm, and September to December 2022, reflecting the post-implementation phase.

Results

This study highlights the potential benefits of using EndoTool IV to manage complex conditions like DKA, with a focus on both clinical and economic outcomes.

  • Incidence of hypoglycemic events reduced from 2.26% to 0.35%, a significant decrease of approximately 84.5%.
  • The number of blood glucose checks decreased by 55%.
  • Average hospital length of stay decreased from 5.1 to 4.5 days.
  • Time required for insulin infusion decreased from 37.2 hours to 35.41 hours, a reduction of 1.79 hours approximately.

Conclusions

  • Clinical Improvements: EndoTool IV led to fewer hypoglycemic events, fewer glucose checks, and shorter infusion times.
  • Financial Impact: While there was no significant reduction in ICU charges, EndoTool IV shows promise in improving clinical outcomes for DKA patients.
  • Future Directions: Further subgroup analysis is being conducted to explore the results in more detail.

References

Authors

Zachary Scheid, DO; Kinza Salim, DO; Josephine Gomes, DO; Danya Abedeen, DO; Rabiah Riaz, MD; Evelyn Calderon Martinez, MD; Lauren Ortiz; Anderson Schrader; Amy Helmuth, DNP, FACHE; Soni Srivastav, MD; Paul Chidester, MD, FACP; Anas Atrash, MD, FACP

Source

23rd Annual Diabetes Technology Meeting

Year

2023

Quick navigation
Objective
Setting
Results
Conclusions
References

Objective

Investigating the impact of implementing EndoTool IV (ETIV), a computerized insulin dosing algorithm, in the treatment of diabetic ketoacidosis (DKA) across a 7-hospital system in Central Pennsylvania.

Setting

UPMC Harrisburg hospital, part of the larger UPMC seven hospital system in Central Pennsylvania. Two distinct time periods were utilized for comparison of outcomes: September to December 2021, representing the pre-implementation phase of the EndoTool IV (ETIV) computerized insulin dosing algorithm, and September to December 2022, reflecting the post-implementation phase.

Results

This study highlights the potential benefits of using EndoTool IV to manage complex conditions like DKA, with a focus on both clinical and economic outcomes.

  • Incidence of hypoglycemic events reduced from 2.26% to 0.35%, a significant decrease of approximately 84.5%.
  • The number of blood glucose checks decreased by 55%.
  • Average hospital length of stay decreased from 5.1 to 4.5 days.
  • Time required for insulin infusion decreased from 37.2 hours to 35.41 hours, a reduction of 1.79 hours approximately.

Conclusions

  • Clinical Improvements: EndoTool IV led to fewer hypoglycemic events, fewer glucose checks, and shorter infusion times.
  • Financial Impact: While there was no significant reduction in ICU charges, EndoTool IV shows promise in improving clinical outcomes for DKA patients.
  • Future Directions: Further subgroup analysis is being conducted to explore the results in more detail.

References

Authors

Zachary Scheid, DO; Kinza Salim, DO; Josephine Gomes, DO; Danya Abedeen, DO; Rabiah Riaz, MD; Evelyn Calderon Martinez, MD; Lauren Ortiz; Anderson Schrader; Amy Helmuth, DNP, FACHE; Soni Srivastav, MD; Paul Chidester, MD, FACP; Anas Atrash, MD, FACP

Source

23rd Annual Diabetes Technology Meeting

Year

2023

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

The objective of this study was to evaluate the impact of renal insufficiency on hypoglycemia rates in patients treated for Diabetic Ketoacidosis (DKA) utilizing a computerized insulin dosing algorithm.
Image
  • Clinical Evidence

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

20 minute read

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

The objective of this study was to evaluate the impact of different blood glucose (BG) target ranges for IV insulin infusions on inpatient glucose metrics, specifically focusing on hypo and hyperglycemic events, duration of IV insulin therapy, and length of stay (LOS) in the hospital.
Image
  • Clinical Evidence

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

To compare the effectiveness of EndoTool IV in reducing hospital LOS and hypoglycemia rates compared to standard insulin infusion protocols.
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.